{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T00:43:01Z","timestamp":1767919381692,"version":"3.49.0"},"reference-count":41,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Parkinson\u2019s disease (PD) is a kind of common neurodegenerative disease in the world. Previous studies have proved that nervonic acid (NA), extracted from <jats:italic>Xanthoceras sorbifolia<\/jats:italic> Bunge, has the potentials of neuroprotection. However, the effect of NA on the PD remained unknown. This study was designed to investigate the NA\u2019s potential function and relative mechanism on motor disorder.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was used for producing parkinsonism motor disorder on male C57BL\/6 mice. Toxicity experiments and behavioral assay were performed to evaluate the effect of NA. Besides, the expression levels of tyrosine hydroxylase and \u03b1-synuclein, as well as striatal dopamine (DA), serotonin, and their metabolites were explored through immunoblotting and chromatography after NA treatment <jats:italic>in vivo<\/jats:italic>.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We found that NA could alleviate the MPTP-induced behavioral deficits dose-dependently. Moreover, NA has no toxic effects on the mouse liver and kidney. Of note, we found that NA significantly reduced the impact of MPTP impairment and striatal DA, serotonin, and metabolites were remained unaffected. In addition, tyrosine hydroxylase was upregulated while \u03b1-synuclein being downregulated and the oxidative stress was partially repressed evidenced by the upregulation of superoxide dismutase and glutathione activity after NA treatment.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our findings unveil NA\u2019s potential for protecting motor system against motor disorder in the PD mouse model without any side effects, indicating NA as an alternative strategy for PD symptom remission.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/tnsci-2020-0171","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T07:46:58Z","timestamp":1622101618000},"page":"237-246","source":"Crossref","is-referenced-by-count":16,"title":["Nervonic acid amends motor disorder in a mouse model of Parkinson\u2019s disease"],"prefix":"10.1515","volume":"12","author":[{"given":"Dandong","family":"Hu","sequence":"first","affiliation":[{"name":"School of Life Science, Northwest Normal University , Lanzhou , Gansu 730070 , People\u2019s Republic of China"},{"name":"Beijing Yanqing District Food and Drug Safety Monitoring Center, Beijing Yanqing Center for Diseases Prevention and Control , Beijing , 102100 , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujuan","family":"Cui","sequence":"additional","affiliation":[{"name":"School of Life Science, Northwest Normal University , Lanzhou , Gansu 730070 , People\u2019s Republic of China"},{"name":"Beijing Yanqing District Food and Drug Safety Monitoring Center, Beijing Yanqing Center for Diseases Prevention and Control , Beijing , 102100 , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji","family":"Zhang","sequence":"additional","affiliation":[{"name":"School of Life Science, Northwest Normal University , Lanzhou , Gansu 730070 , People\u2019s Republic of China"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,5,25]]},"reference":[{"key":"2022092407354058535_j_tnsci-2020-0171_ref_001","doi-asserted-by":"crossref","unstructured":"Politis M. Neuroimaging in Parkinson disease: from research setting to clinical practice. Nat Rev Neurol. 2014 Dec;10(12):708\u201322.","DOI":"10.1038\/nrneurol.2014.205"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_002","doi-asserted-by":"crossref","unstructured":"Duncan GW. The aging brain and neurodegenerative diseases. Clin Geriatr Med. 2011 Nov;27(4):629\u201344.","DOI":"10.1016\/j.cger.2011.07.008"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_003","doi-asserted-by":"crossref","unstructured":"Aarsland D, Creese B, Politis M, Chaudhuri KR, Ffytche DH, Weintraub D, et al. Cognitive decline in Parkinson disease. Nat Rev Neurol. 2017 Apr;13(4):217\u201331.","DOI":"10.1038\/nrneurol.2017.27"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_004","doi-asserted-by":"crossref","unstructured":"Schapira AH, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017 Jul;18(7):435\u201350. Erratum in: Nat Rev Neurosci. 2017 Jul;18(7):509.","DOI":"10.1038\/nrn.2017.62"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_005","doi-asserted-by":"crossref","unstructured":"Lees AJ, Hardy J, Revesz T. Parkinson\u2019s disease. Lancet. 2009 Jun;373(9680):2055\u201366.","DOI":"10.1016\/S0140-6736(09)60492-X"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_006","doi-asserted-by":"crossref","unstructured":"Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, et al. Serotonergic pathology and disease burden in the premotor and motor phase of A53T \u03b1-synuclein parkinsonism: a cross-sectional study. Lancet Neurol. 2019 Aug;18(8):748\u201359.","DOI":"10.1016\/S1474-4422(19)30140-1"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_007","doi-asserted-by":"crossref","unstructured":"Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014 Apr;311(16):1670\u201383.","DOI":"10.1001\/jama.2014.3654"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_008","doi-asserted-by":"crossref","unstructured":"Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease \u2013 repurposed drugs and new approaches. Nat Rev Neurol. 2019 Apr;15(4):204\u201323.","DOI":"10.1038\/s41582-019-0155-7"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_009","doi-asserted-by":"crossref","unstructured":"Dehay B, Bourdenx M, Gorry P, Przedborski S, Vila M, Hunot S, et al. Targeting \u03b1-synuclein for treatment of Parkinson\u2019s disease: mechanistic and therapeutic considerations. Lancet Neurol. 2015 Aug;14(8):855\u201366.","DOI":"10.1016\/S1474-4422(15)00006-X"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_010","doi-asserted-by":"crossref","unstructured":"Ishikawa T, Funahashi T, Kudo J. Effectiveness of the Kampo kami-shoyo-san (TJ-24) for tremor of antipsychotic-induced parkinsonism. Psychiatry Clin Neurosci. 2000 Oct;54(5):579\u201382.","DOI":"10.1046\/j.1440-1819.2000.00756.x"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_011","doi-asserted-by":"crossref","unstructured":"Meng DL, Shang L, Feng XH, Huang XF, Che X. Xanthoceraside hollow gold nanoparticles, green pharmaceutics preparation for poorly water-soluble natural anti-AD medicine. Int J Pharm. 2016 Jun;506(1\u20132):184\u201390.","DOI":"10.1016\/j.ijpharm.2016.04.042"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_012","doi-asserted-by":"crossref","unstructured":"Xiao W, Wang Y, Zhang P, Li N, Jiang S, Wang JH, et al. Bioactive barrigenol type triterpenoids from the leaves of Xanthoceras sorbifolia Bunge. Eur J Med Chem. 2013 Feb;60:263\u201370.","DOI":"10.1016\/j.ejmech.2012.12.022"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_013","doi-asserted-by":"crossref","unstructured":"Dhobale MV, Wadhwani N, Mehendale SS, Pisal HR, Joshi SR. Reduced levels of placental long chain polyunsaturated fatty acids in preterm deliveries. Prostaglandins Leukot Essent Fatty Acids. 2011 Sep-Oct;85(3\u20134):149\u201353.","DOI":"10.1016\/j.plefa.2011.06.003"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_014","doi-asserted-by":"crossref","unstructured":"Amminger GP, Sch\u00e4fer MR, Klier CM, Slavik JM, Holzer I, Holub M, et al. Decreased nervonic acid levels in erythrocyte membranes predict psychosis in help-seeking ultra-high-risk individuals. Mol Psychiatry. 2012 Dec;17(12):1150\u20132.","DOI":"10.1038\/mp.2011.167"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_015","doi-asserted-by":"crossref","unstructured":"Kageyama Y, Kasahara T, Nakamura T, Hattori K, Deguchi Y, Tani M, et al. Plasma nervonic acid is a potential biomarker for major depressive disorder: a pilot study. Int J Neuropsychopharmacol. 2018 Mar;21(3):207\u201315.","DOI":"10.1093\/ijnp\/pyx089"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_016","doi-asserted-by":"crossref","unstructured":"Vozella V, Basit A, Misto A, Piomelli D. Age-dependent changes in nervonic acid-containing sphingolipids in mouse hippocampus. Biochim Biophys Acta Mol Cell Biol Lipids. 2017 Dec;1862(12):1502\u201311.","DOI":"10.1016\/j.bbalip.2017.08.008"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_017","doi-asserted-by":"crossref","unstructured":"Ozkizilcik A, Sharma A, Lafuente JV, Muresanu DF, Castellani RJ, Nozari A, et al. Nanodelivery of cerebrolysin reduces pathophysiology of Parkinson\u2019s disease. Prog Brain Res. 2019;245:201\u201346.","DOI":"10.1016\/bs.pbr.2019.03.014"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_018","doi-asserted-by":"crossref","unstructured":"Rosa AI, Duarte-Silva S, Silva-Fernandes A, Nunes MJ, Carvalho AN, Rodrigues E, et al. Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson\u2019s disease. Mol Neurobiol. 2018 Dec;55(12):9139\u201355.","DOI":"10.1007\/s12035-018-1062-4"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_019","doi-asserted-by":"crossref","unstructured":"Ferrazzo S, Gunduz-Cinar O, Stefanova N, Pollack GA, Holmes A, Schmuckermair C, et al. Increased anxiety-like behavior following circuit-specific catecholamine denervation in mice. Neurobiol Dis. 2019 May;125:55\u201366.","DOI":"10.1016\/j.nbd.2019.01.009"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_020","doi-asserted-by":"crossref","unstructured":"Hedya SA, Safar MM, Bahgat AK. Cilostazol mediated Nurr1 and autophagy enhancement: neuroprotective activity in rat rotenone PD model. Mol Neurobiol. 2018 Sep;55(9):7579\u201387.","DOI":"10.1007\/s12035-018-0923-1"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_021","doi-asserted-by":"crossref","unstructured":"Khasnavis S, Ghosh A, Roy A, Pahan K. Castration induces Parkinson disease pathologies in young male mice via inducible nitric-oxide synthase. J Biol Chem. 2013 Jul;288(29):20843\u201355.","DOI":"10.1074\/jbc.M112.443556"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_022","doi-asserted-by":"crossref","unstructured":"Gagnaire F, Chalansonnet M, Carabin N, Micillino JC. Effects of subchronic exposure to styrene on the extracellular and tissue levels of dopamine, serotonin and their metabolites in rat brain. Arch Toxicol. 2006 Oct;80(10):703\u201312.","DOI":"10.1007\/s00204-006-0083-3"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_023","doi-asserted-by":"crossref","unstructured":"Ngwa HA, Kanthasamy A, Jin H, Anantharam V, Kanthasamy AG. Vanadium exposure induces olfactory dysfunction in an animal model of metal neurotoxicity. Neurotoxicology. 2014 Jul;43:73\u201381.","DOI":"10.1016\/j.neuro.2013.12.004"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_024","doi-asserted-by":"crossref","unstructured":"Lionetto L, Lostia AM, Stigliano A, Cardelli P, Simmaco M. HPLC-mass spectrometry method for quantitative detection of neuroendocrine tumor markers: vanillylmandelic acid, homovanillic acid and 5-hydroxyindoleacetic acid. Clin Chim Acta. 2008 Dec;398(1\u20132):53\u20136.","DOI":"10.1016\/j.cca.2008.08.003"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_025","doi-asserted-by":"crossref","unstructured":"Al-Mukhaini N, Ba-Omar T, Eltayeb E, Al-Shihi A, Al-Riyami N, Al-Belushi J, et al. Liver and kidney toxicity induced by Afzal smokeless tobacco product in Oman. Tissue Cell. 2017 Apr;49(2 2 Pt B):307\u201314.","DOI":"10.1016\/j.tice.2017.01.008"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_026","doi-asserted-by":"crossref","unstructured":"Breit S, Lessmann L, Unterbrink D, Popa RC, Gasser T, Schulz JB. Lesion of the pedunculopontine nucleus reverses hyperactivity of the subthalamic nucleus and substantia nigra pars reticulata in a 6-hydroxydopamine rat model. Eur J Neurosci. 2006 Oct;24(8):2275\u201382.","DOI":"10.1111\/j.1460-9568.2006.05106.x"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_027","doi-asserted-by":"crossref","unstructured":"Shook BC, Rassnick S, Osborne MC, Davis S, Westover L, Boulet J, et al. In vivo characterization of a dual adenosine A2A\/A1 receptor antagonist in animal models of Parkinson\u2019s disease. J Med Chem. 2010 Nov;53(22):8104\u201315.","DOI":"10.1021\/jm100971t"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_028","doi-asserted-by":"crossref","unstructured":"Duty S, Jenner P. Animal models of Parkinson\u2019s disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol. 2011 Oct;164(4):1357\u201391.","DOI":"10.1111\/j.1476-5381.2011.01426.x"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_029","doi-asserted-by":"crossref","unstructured":"Karunakaran S, Saeed U, Mishra M, Valli RK, Joshi SD, Meka DP, et al. Selective activation of p38 mitogen-activated protein kinase in dopaminergic neurons of substantia nigra leads to nuclear translocation of p53 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice. J Neurosci. 2008 Nov;28(47):12500\u20139.","DOI":"10.1523\/JNEUROSCI.4511-08.2008"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_030","doi-asserted-by":"crossref","unstructured":"Homayoun H. Parkinson disease. Ann Intern Med. 2018 Sep;169(5):ITC33\u201348.","DOI":"10.7326\/AITC201809040"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_031","doi-asserted-by":"crossref","unstructured":"Viaro R, Marti M, Morari M. Dual motor response to l-dopa and nociceptin\/orphanin FQ receptor antagonists in 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) treated mice: paradoxical inhibition is relieved by D(2)\/D(3) receptor blockade. Exp Neurol. 2010 Jun;223(2):473\u201384.","DOI":"10.1016\/j.expneurol.2010.01.014"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_032","doi-asserted-by":"crossref","unstructured":"Zhang QS, Heng Y, Mou Z, Huang JY, Yuan YH, Chen NH. Reassessment of subacute MPTP-treated mice as animal model of Parkinson\u2019s disease. Acta Pharmacol Sin. 2017 Oct;38(10):1317\u201328.","DOI":"10.1038\/aps.2017.49"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_033","doi-asserted-by":"crossref","unstructured":"Vila M, Vukosavic S, Jackson-Lewis V, Neystat M, Jakowec M, Przedborski S. Alpha-synuclein up-regulation in substantia nigra dopaminergic neurons following administration of the Parkinsonian toxin MPTP. J Neurochem. 2000 Feb;74(2):721\u20139.","DOI":"10.1046\/j.1471-4159.2000.740721.x"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_034","doi-asserted-by":"crossref","unstructured":"Lewkowicz N, Pi\u0105tek P, Namieci\u0144ska M, Domowicz M, Bonikowski R, Szemraj J, et al. Naturally occurring nervonic acid ester improves myelin synthesis by human oligodendrocytes. Cells. 2019 Jul;8(8):786.","DOI":"10.3390\/cells8080786"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_035","doi-asserted-by":"crossref","unstructured":"Murphy EJ. The blood-brain barrier and protein-mediated fatty acid uptake: role of the blood-brain barrier as a metabolic barrier: an editorial comment for \u2018the blood-brain barrier fatty acid transport protein 1 (FATP1\/SLC27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport\u2019. J Neurochem. 2017 May;141(3):324\u2013329.","DOI":"10.1111\/jnc.14000"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_036","doi-asserted-by":"crossref","unstructured":"Brichta L, Greengard P, Flajolet M. Advances in the pharmacological treatment of Parkinson\u2019s disease: targeting neurotransmitter systems. Trends Neurosci. 2013 Sep;36(9):543\u201354.","DOI":"10.1016\/j.tins.2013.06.003"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_037","doi-asserted-by":"crossref","unstructured":"Li XZ, Zhang SN, Liu SM, Lu F. Recent advances in herbal medicines treating Parkinson\u2019s disease. Fitoterapia. 2013 Jan;84:273\u201385.","DOI":"10.1016\/j.fitote.2012.12.009"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_038","doi-asserted-by":"crossref","unstructured":"Mizuno Y, Nomoto M, Hasegawa K, Hattori N, Kondo T, Murata M, et al. Rotigotine vs ropinirole in advanced stage Parkinson\u2019s disease: a double-blind study. Parkinsonism Relat Disord. 2014 Dec;20(12):1388\u201393.","DOI":"10.1016\/j.parkreldis.2014.10.005"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_039","doi-asserted-by":"crossref","unstructured":"Poewe W, Seppi K, Fitzer-Attas CJ, Wenning GK, Gilman S, Low PA, et al. Efficacy of rasagiline in patients with the Parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2015 Feb;14(2):145\u201352.","DOI":"10.1016\/S1474-4422(14)70288-1"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_040","doi-asserted-by":"crossref","unstructured":"Bonuccelli U. Comparing dopamine agonists in Parkinson\u2019s disease. Curr Opin Neurol. 2003 Dec;16(Suppl 1):S13\u20139.","DOI":"10.1097\/00019052-200312001-00004"},{"key":"2022092407354058535_j_tnsci-2020-0171_ref_041","doi-asserted-by":"crossref","unstructured":"Stowe R, Ives N, Clarke CE, Deane K, Wheatley K, Gray R, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson\u2019s disease patients with motor complications. Cochrane Libr. 2010 Jul;7:CD007166.","DOI":"10.1002\/14651858.CD007166.pub2"}],"updated-by":[{"DOI":"10.1515\/tnsci-2022-0450","type":"retraction","label":"Retraction","source":"retraction-watch","updated":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"record-id":"36986"}],"container-title":["Translational Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2020-0171\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2020-0171\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T07:36:00Z","timestamp":1664004960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/tnsci-2020-0171\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,5,25]]},"published-print":{"date-parts":[[2021,5,25]]}},"alternative-id":["10.1515\/tnsci-2020-0171"],"URL":"https:\/\/doi.org\/10.1515\/tnsci-2020-0171","relation":{},"ISSN":["2081-6936"],"issn-type":[{"value":"2081-6936","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}